| scholarly article | Q13442814 |
| P953 | full work available at URL | http://www.bloodjournal.org/cgi/content/abstract/79/2/473 |
| P698 | PubMed publication ID | 1370388 |
| P2093 | author name string | D. Treille | |
| T. Tsuruo | |||
| D. Fiere | |||
| D. Guyotat | |||
| E. Archimbaud | |||
| L. Campos | |||
| Calmard-Oriol P | |||
| J. Troncy | |||
| P. Calmard-Oriol | |||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | multiple drug resistance | Q643839 |
| P304 | page(s) | 473-476 | |
| P577 | publication date | 1992-01-01 | |
| 1992-01-15 | |||
| P1433 | published in | Blood | Q885070 |
| P1476 | title | Clinical significance of multidrug resistance P-glycoprotein expression on acute nonlymphoblastic leukemia cells at diagnosis | |
| P478 | volume | 79 |
| Q36555764 | 12-O-tetradecanoylphorbol-13-acetate activation of the MDR1 promoter is mediated by EGR1 |
| Q39089915 | A novel SERCA inhibitor demonstrates synergy with classic SERCA inhibitors and targets multidrug-resistant AML. |
| Q54185189 | A pilot study of amiodarone with infusional doxorubicin or vinblastine in refractory breast cancer. |
| Q35171274 | ABC transporters in multi-drug resistance and ADME-Tox of small molecule tyrosine kinase inhibitors |
| Q36689418 | AML-MO: clinical entity or waste basket for immature blastic leukemias? A description of 14 patients. Dutch Slide Review Committee of Leukemias in Adults |
| Q33841438 | Allogeneic hematopoietic stem cell transplantation for the treatment of high-risk acute myelogenous leukemia and myelodysplastic syndrome using reduced-intensity conditioning with fludarabine and melphalan |
| Q40388183 | Anthracycline antibiotics in cancer therapy. Focus on drug resistance |
| Q45036307 | Anthracycline drugs and MDR expression in human leukemia |
| Q40534105 | Antibodies in the study of multiple drug resistance |
| Q63385905 | Association between P-glycoprotein and lymphoid antigen expression on myeloblasts versus therapy response and survival in de novo acute myeloid leukemia: long-term follow-up results |
| Q41541083 | Classical multidrug resistance in acute myeloid leukaemia |
| Q89994575 | Clinical Significance of ABCB1 in Acute Myeloid Leukemia: A Comprehensive Study |
| Q54239488 | Comparative effects of racemic verapamil vs R-verapamil on normal and leukemic progenitors. |
| Q36081370 | Cyclosporin A and doxorubicin-ifosfamide in resistant solid tumours: a phase I and an immunological study |
| Q36080042 | Daunorubicin pharmacokinetics and the correlation with P-glycoprotein and response in patients with acute leukaemia |
| Q33180943 | Development of multidrug-resistance convertors: sense or nonsense? |
| Q54183829 | Dexverapamil as resistance modifier in acute myeloid leukaemia. |
| Q58605916 | Evidence of a role for functional heterogeneity in multidrug resistance transporters in clinical trials of P-glycoprotein modulation in acute myeloid leukemia |
| Q54263700 | Flow cytometric analysis of P-glycoprotein in normal and leukemic cells |
| Q34218136 | Generation of a drug resistance profile by quantitation of mdr-1/P-glycoprotein in the cell lines of the National Cancer Institute Anticancer Drug Screen |
| Q36677320 | High BAALC expression associates with other molecular prognostic markers, poor outcome, and a distinct gene-expression signature in cytogenetically normal patients younger than 60 years with acute myeloid leukemia: a Cancer and Leukemia Group B (CAL |
| Q36141213 | Human hepatoma cells rich in P-glycoprotein are sensitive to aclarubicin and resistant to three other anthracyclines |
| Q41393111 | In vitro activity of S 9788 on a multidrug-resistant leukemic cell line and on normal hematopoietic cells-reversal of multidrug resistance by sera from phase I-treated patients |
| Q44003315 | In vivo use of all-trans retinoic acid prior to induction chemotherapy improves complete remission rate and increases rhodamine 123 uptake in patients with de novo acute myeloid leukemia |
| Q41972709 | Increased mdr1 gene transcript levels in high-grade carcinoma of the bladder determined by quantitative PCR-based assay |
| Q35977393 | MDR1 gene expression in primary colorectal carcinomas |
| Q33758413 | Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: a phase III trial (E2995) |
| Q71019800 | Modulation of multidrug resistance by BIBW22BS in blasts of de novo or relapsed or persistent acute myeloid leukemia ex vivo |
| Q40535284 | Multidrug resistance (MDR) genes in haematological malignancies |
| Q42186987 | Multidrug resistance 1 gene expression and AgNOR in childhood acute leukemias |
| Q54170739 | Multidrug resistance gene (mdr1) RNA levels in relation to P-glycoprotein content of leukemic cells from patients with acute leukemia. |
| Q41052675 | Multidrug resistance in cancer chemotherapy |
| Q41175781 | Multidrug resistance in pediatric oncology |
| Q42859166 | Multidrug resistance phenotype in leukaemic cells from patients with acute myelocytic leukaemia can be detected with 99Tc(m)-MIBI. |
| Q41340654 | New flow cytometric method for detection of minimally expressed multidrug resistance P-glycoprotein on normal and acute leukemia cells using biotinylated MRK16 and streptavidin-RED670 conjugate |
| Q64076519 | Nkx-2.5 Regulates MDR1 Expression via Its Upstream Promoter in Breast Cancer Cells |
| Q36771977 | Oncogene- and drug resistance-associated alternative exon usage in acute myeloid leukemia (AML). |
| Q36331759 | Overexpression of lung resistance-related protein and P-glycoprotein and response to induction chemotherapy in acute myelogenous leukemia |
| Q36080651 | P-glycoprotein and glutathione S-transferase pi in childhood acute lymphoblastic leukaemia |
| Q35976039 | P-glycoprotein expression in normal and reactive bone marrows |
| Q27024260 | P-glycoprotein inhibitors of natural origin as potential tumor chemo-sensitizers: A review |
| Q40630952 | P-glycoprotein, multidrug resistance and tumor progression |
| Q45871082 | P-glycoprotein-mediated multidrug resistance in normal and neoplastic hematopoietic cells |
| Q53024621 | PCR-determined expression of the MDR1 gene in chronic lymphocytic leukemia |
| Q40535280 | Pharmacologic circumvention of multidrug resistance |
| Q33929477 | Promising approaches in acute leukemia |
| Q73686148 | Quantitative analysis of human multidrug resistance 1 (MDR1) gene expression by nonisotopic competitive reverse transcriptase polymerase chain reaction assay |
| Q36140996 | Quantitative analysis of multidrug resistance gene expression in human osteosarcomas |
| Q36021212 | Revealing the fate of cell surface human P-glycoprotein (ABCB1): The lysosomal degradation pathway. |
| Q36749396 | Targeting a DNA binding motif of the EVI1 protein by a pyrrole-imidazole polyamide |
| Q40514016 | The biology of the P-glycoproteins |
| Q88809961 | The challenge of drug resistance in cancer treatment: a current overview |
| Q38999278 | The clinical relevance and prognostic significance of adenosine triphosphate ATP-binding cassette (ABCB5) and multidrug resistance (MDR1) genes expression in acute leukemia: an Egyptian study |
| Q40620465 | The effect of MDR-1 gene expression on outcome in acute myeloblastic leukaemia |
| Q35828140 | The impact of insulin on chemotherapeutic sensitivity to 5-fluorouracil in gastric cancer cell lines SGC7901, MKN45 and MKN28. |
| Q36079661 | Treatment of adult T-cell leukaemia-lymphoma with irinotecan hydrochloride (CPT-11). CPT-11 Study Group on Hematological Malignancy |
| Q34360283 | Zosuquidar, a novel modulator of P-glycoprotein, does not improve the outcome of older patients with newly diagnosed acute myeloid leukemia: a randomized, placebo-controlled trial of the Eastern Cooperative Oncology Group 3999 |
| Q45098735 | p-Glycoprotein expression as a predictor of breast cancer recurrence |
Search more.